Santarus, Inc. (NASDAQ:SNTS)

CAPS Rating: 2 out of 5

A pharmaceutical company focused on acquiring, developing and commercializing proprietary products that address the needs of patients treated by gastroenterologists or primary care physicians.

Recs

0
Player Avatar 21popsontop (< 20) Submitted: 10/14/2010 1:31:12 AM : Outperform Start Price: $3.10 SNTS Score: +81.10

This longshot looks like a warrior on a bear hunt.

Featured Broker Partners


Advertisement